biostudies-literatureMcSkane MNCI NIH HHS215-222.e3https://www.ebi.ac.uk/biostudies/studies/S-EPMC7496217biostudies-literatureUnknown17(3)<h4>Background</h4>Previous studies have found significant relationships between height and colorectal cancer (CRC) risk. Increased growth has been associated with activated pathways such as insulin-like growth factor 1. This study examined the impact of height on outcomes in metastatic CRC patients enrolled onto the FIRE-3 study, a randomized phase 3 clinical trial.<h4>Patients and methods</h4>A total of 695 patients with metastatic CRC were studied and height was measured in centimeters. Male patients were grouped as ≤ 165, 166-175, 176-185, and ≥ 186 cm in height; female patients were grouped as ≤ 154, 155-164, 165-174, and ≥ 175 cm in height. Primary end point was overall survival (OS); secondary end point was progression-free survival.<h4>Results</h4>When patients' heights were categoClinical colorectal cancerAssociation Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.PMC7496217P30 CA014089Puccini AHeinemann VStintzing SLenz HJMcSkane MCao SJelas INaseem MfalseAssociation Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.<h4>Background</h4>Previous studies have found significant relationships between height and colorectal cancer (CRC) risk. Increased growth has been associated with activated pathways such as insulin-like growth factor 1. This study examined the impact of height on outcomes in metastatic CRC patients enrolled onto the FIRE-3 study, a randomized phase 3 clinical trial.<h4>Patients and methods</h4>A total of 695 patients with metastatic CRC were studied and height was measured in centimeters. Male patients were grouped as ≤ 165, 166-175, 176-185, and ≥ 186 cm in height; female patients were grouped as ≤ 154, 155-164, 165-174, and ≥ 175 cm in height. Primary end point was overall survival (OS); secondary end point was progression-free survival.<h4>Results</h4>When patients' heights were catego2018-01-01T00:00:00Z2018 Sep2025-04-04T01:37:00.484Z2020-09-20T07:01:32ZS-EPMC74962172988043610.1016/j.clcc.2018.05.003